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1 Purpose of document 
 
The NICE draft lipid modification guidelines, published in February 2014[1], recommend 
QRISK2[2] is used to assess cardiovascular risk. There are two exceptions to this. One is 
where the patient has chronic kidney disease. The other exception is when the patient has 
diabetes where the guideline recommends the use of the UKPDS for type 2 diabetes[3] and 
no risk assessment for patients with type 1 diabetes. This paper summarises the evidence 
for the use of UKPDS in patients with diabetes and presents new information on the 
validation of QRISK2 in the subset of patients with diabetes. 
 
2 Background 
 
UKPDS Risk Engine (http://www.dtu.ox.ac.uk/riskengine/) is a type 2 diabetes-specific risk 
calculator for estimating the 10-year risk of CHD (fatal and non-fatal MI, and sudden cardiac 
death) and stroke (both fatal and non-fatal). The original paper for predicting CHD published 
in 2001 by Stevens et al[3] identified a number of limitations of UKPDS since the model was 
derived from patients recruited for a randomised controlled trial and so was limited to 
patients  aged 25 to 65 years. Stevens et al also concluded that “ideally, the model would be 
derived from a large-scale epidemiological study of diabetic patients”.  
The draft lipid guideline prefers the UKPDS because it has been validated specifically in 
patients with diabetes whereas QRISK2 has been validated in populations which include 
diabetics but not in the subset alone. This paper reviews aspects of the lipid guidance in 
relation to this decision. Specifically it  
 compares the populations used to derive the current version of QRISK2 vs UKPDS.  
 reviews the evidence from the validation studies cited in the lipid guidance.  
 presents original results for the performance of QRISK2 specifically in the subset of 
patients with diabetes so that the results can be compared with the published 
literature.  
 
3 Comparison of development and use of QRISK2 & 
UKPDS 
Table 1 compares the populations used to derive QRISK (2014) and UKPDS (2001). The 
salient points are: 
1. Cohort definition: UKPDS is based on 4,540 newly diagnosed patients with diabetes 
referred to hospital clinics between 1977 to 1991 whereas QRISK2 (2014) was 
developed using a cohort of 3.6 million patients of which 48,889 patients with 
prevalent type 2 diabetes within primary care. Since the purpose of the risk 
assessment is not limited to newly diagnosed patients, and will mainly take place 
within primary care, the population used for QRISK2 is likely to be more suitable.  
 
 
2. Update: The UKPDS has not been updated for 15 years (data capture until 1997) 
whereas QRISK2 is updated annually (currently on data captured until 2013). This is 
important since the population has changed significantly over that time both in 
terms of the incidence of CVD but also the prevalence of risk factors relevant to CVD 
risk assessment.  
3. Outcomes: QRISK2 predicts absolute risk of CVD which is the key outcome of 
interest. In contrast the version of UKPDS included in the draft recommendation by 
NICE (p75) recommends calculating the risk of CHD and stroke separately and then 
adding them together[1]. This results in double counting as the outcomes are not 
mutually exclusive and the CHD and Stroke models include different predictor 
variables. This will result in inaccurate predictions and overestimation of risk 
compared with a score designed to predict risk of the relevant outcome. The UKPDS 
website itself states “Summing the coronary heart disease (CHD) and stroke risk 
estimates from the Risk Engine is not recommended” 
4. Age range: QRISK2 has been developed and can be applied to patients aged 25-84 
years. UKPDS was developed in patients aged 25-65 so doesn’t apply to the relevant 
age range. The draft guideline doesn’t make this clear. 
5. Predictors: UKPDS does not include some well-established predictors such as 
deprivation, family history, body mass index, rheumatoid arthritis, chronic renal 
disease or treated hypertension. UKPDS will tend to under-estimate risk in patients 
with these factors.  Recent updates of QRISK2 include both type 1 and type 2 
diabetes as predictor variables [ref]. 
Regarding ethnicity, while UKPDS risk engine at first sight appears to have three 
options (White, Afro-Caribbean and Asian-Indian) as these were used in the initial 
modelling, the resulting algorithm in fact only uses two for the CHD outcomes and 
none for the Stroke outcome[4]  Entering White or Asian-Indian give the same 
answers for CHD and changing the ethnicity drop down makes no difference at all for 
Stroke.  There is no ‘black African’ category – a group that nowadays makes up a 
large proportion of some practices and who do not fit with the binary category for 
ethnicity included in the UKPDS CHD model. It is well known that CVD risk and the 
prevalence of risk factors for CHD and Stroke vary considerably between ethnic 
groups and a risk score should reflect these differences[5].  QRISK2, however, 
includes an ethnicity variable with 9 categories[2].  
6. HBA1C: HBA1C was included as a predictor in the UKPDS CHD model[3] but it was 
not significant for stroke and so wasn’t included[4]. In the UKPDS CHD model, HBA1C 
is entered as a % whereas now it is measured in mmol/l so a conversion would be 
needed. Further evidence from other studies has found that the addition of HBA1c 
to a version of Framingham is marginally better than Framingham alone for 
predicting CHD but this was only a small statistically significant improvement in 
discrimination in men but not women and without improvement in reclassification of 
risk category[6].  
7. QRISK2 is integrated within GP systems so that the risk score can be automatically 
calculated and recorded in the record for patients without the need to do separate 
data entry.  The UKPDS risk engine requires separate data entry making CVD risk 
assessment more time consuming and error prone.  
 
 
Table 1 Comparison of QRISK2 and UKPDS derivation cohorts and model inputs 
 QRISK2 2014 UKPDS 
(Stevens 2001) 
Derivation cohort Total of 3.6 million patients (1998-
2013) including 
58,613  patients with prevalent 
diabetes (48,889 cases with  
type 2 diabetes) 
4540 newly diagnosed, hospital-
referred patients with type2 
diabetes for CHD model 
4549 patients included in the stroke 
model 
Time period for 
follow-up 
1998-2013 1977-1997 
Date last updated Jan 2014 Published 2001 
outcome CVD  2 separate outcomes:  
CHD & Stroke 
To get CVD risk then add CHD and 
stroke risks (not recommended by 
Stevens et al) 
Outcome numbers 795 CVD events (in type 1) 
10,643 CVD events(in type 2) 
Not reported for CHD 
There were 188 strokes 
Age range 25-84 years 25-65 years 
ethnicity  9 levels: 
White/not recorded, Indian, Pakistani, 
Bangladeshi, other Asian, black 
African, black Caribbean, Chinese, 
other including mixed 
2 levels for CHD model - Afro 
Caribbean vs other. 
Ethnicity was not included in the 
stroke model 
deprivation Townsend score - 
sex M/F M/F 
smoking status  5 levels: 
Non-smoker, ex-smoker, current – 
light, current – moderate, current-
heavy 
 current smoker vs other 
Family history CHD 
under 60 years 
Yes/no - 
atrial fibrillation Yes/no Yes/no but only included in the 
stroke model 
Chronic renal disease Yes/no - 
Rheumatoid arthritis Yes/no - 
Treated hypertension Yes/no - 
Type 1 diabetes Yes/no - 
Type2 diabetes Yes/no - 
Body mass index Continuous  
systolic blood 
pressure  
Continuous Continuous 
total cholesterol & 
HDL 
Ratio of total/HDL Ratio of total/HDL 
HBA1c - Yes but only included in the CHD 
model, not in stroke in CHD, no in 
Stroke 
 
 
Duration diabetes - Yes 
 
3.1 Validation studies of UKPDS 
The draft lipid guideline refers to a number of validation studies of UKPDS compared with 
Framingham in patients with diabetes. None of these studies tested the modification of the 
UKPDS suggested by NICE – namely the arithmetic addition of the risk of CHD plus the risk of 
stroke determined by two separately modelled equations with different parameters. 
a. Validation study by Stephens (2004): The study by Stephens et al [7] compared 
UKPDS with Framingham in a selected sample of 798 patients from a London hospital 
clinic with 358 CVD events during follow-up. The study included a mixture of patients 
with type 1 and type 2 diabetes. The results showed Framingham performed 
substantially better than UKPDS with ROC values of 0.80 for Framingham compared 
with 0.74 for UKPDS[7]. The calibration of both UKPDS & Framingham was poor with 
significant under-prediction which the authors think could be related to the selection 
of hospital patients likely to be at higher risk than patients in primary care. Stephens 
et al also suggest that inclusion of BMI (which is not included in UKPDS) may improve 
risk prediction. 
 
b. Validation study by Guzder (2005)[8]: This study examined 428 newly diagnosed 
type 2 diabetics from an affluent predominantly white population in Dorset. There 
were 98 CVD events. Discrimination for UKPDS was 0.67 compared with 0.66 for 
framingham. Calibration of both models was reported to be poor. 
 
c. Validation study by Elkeles (2008) [9]: this study examined 576 patients with type 2 
diabetes recruited from a London hospital clinic. They excluded black people. There 
were 66 CVD events with a ROC value of 0.63 for version 3 of UKPDS (which was the 
same as the value of 0.63 reported for Framingham). Calibration was not reported. 
 
d. Validation study by Simmons (2009) [10]: this study validated both UKPDS and 
Framingham in 272 patients with type 1 & type 2 diabetes from Norfolk. The analysis 
was restricted to patients with complete data and those aged 40-79 years. All 
patients were white. There were 69 CVD events. The study found UKPDS was well 
calibrated and better than Framingham.  However more patients were correctly 
classified with Framingham than Framingham and there was no statistically 
significant difference with UKPDS (ROC value for Framingham was 0.73 compared 
with 0.72 for UKPDS). The authors concluded that further testing of UKPDS is needed 
before it can replace Framingham[10] though there are no more recent papers cited 
providing evidence of further testing.  
 
  
 
 
Table 2 Summary of UKPDS validation information included in draft lipid guidance 
(2014)[1].  
 
Source Validation cohort Numb
er of 
CVD 
events 
End point 
measured 
Version 
UKPDS 
tested* 
AUROC Calibration/reclassifi
cation 
Stephens 
2004[7] 
798 patients with 
type1 & type 2 
diabetes 1990-2001 
London Hospital 
Diabetes clinic   
35-74 years 
358  CVD + 
PVD 
Version 1 0.74  
(0.70-0.78) 
Poor calibration with 
significant under 
prediction.  
 
Guzder 
2005 [8] 
428 newly diagnosed 
type 2 diabetics 30-74 
years from Poole 1996-
1998. Affluent white 
population. 
98 CHD 
events 
Version 1 0.67  Poor calibration.  
Discrimination & 
calibration no better 
than framingham  
Elkeles 
2008[9] 
576 patients type 2 
diabetes recruited 
from outpatient clinics, 
central & west London 
aged 50-75 years; 
excluded black people. 
Median follow-up 4 
years 
66  
 
CVD Version 3  0.63  
(0.56-0.71) 
Not reported 
Simmons 
2009[10]  
272 type 1& 2 
diabetes, white 
patients from Norfolk. 
Analysis restricted to 
patients with complete 
data. Aged 40-79 
recruited 1993-8. 
Followed up until 2007 
 
69  
 
CVD Version 3 0.72 
(0.65-0.78) 
UKPDS no significant 
difference in 
reclassification or 
discrimination c.f. 
Framingham. 
 
*Version 1 of UKPDS predicts CHD and stroke risks separately. Version 3 UKPDS predicts combined 
CVD outcome. There are no validation studies of the NICE modified version of UKPDS which sums 
CHD and stroke risk. 
  
 
 
4 Methods for validation of QRISK2 (2014):  
 
In light of the draft lipid guideline, we have undertaken a validation of the latest version of 
QRISK2 (2014) in the subset of patients with diabetes using version 36 of the QResearch 
database (updated until 01 Aug 2013). QRISK2-2014 was derived using an open cohort of 
patients aged 25 to 84 registered with the practices from 01 Jan 1998 until 01 Aug 2013.  
We tested the performance of QRISK2(2014) in the validation cohort in  patients with type 1 
diabetes and patients with type 2 diabetes 
 
We calculated the ROC values, D statistics and R2 values, and assessed calibration by 
comparing observed risks with mean predicted risks across tenths of predicted risks. We 
used multiple imputation in the derivation and the validation cohorts to impute missing 
values for systolic blood pressure, cholesterol/HDL ratio, smoking status, and body mass 
index and combined results across the imputed datasets in the analyses.  
 
We also derived a separate model based on the subset of patients with a diagnosis of 
diabetes and including HBA1C as a continuous variable and duration of diabetes as a 
categorical variable (<1; 1-4; 5-9; 10+ years) as well as the usual variables already in QRISK2 
but found no significant improvement in the validation statistics. 
 
 
5 Results of QRISK2 validation  
 
5.1 Baseline characteristics 
Table 3 shows the baseline characteristics of patients with either type 1 or type 2 diabetes 
in the derivation and validation cohorts. 
 
Table 3 characteristics of all patients aged 25-84 years in the QRISK2 derivation and 
validation cohorts with either type 1 or type 2 diabetes.  
 Derivation cohort Validation cohort 
 Type 2 Type1 Type 2 Type 1 
total 48889   (100.0) 9724    (100.0) 26759   (100.0) 5588    (100.0) 
female 22128   (45.3) 4453    (45.8) 12267   (45.8) 2546    (45.6) 
male 26761   (54.7) 5271    (54.2) 14492   (54.2) 3042    (54.4) 
25-34 years 1201    (2.5) 4522    (46.5) 777     (2.9) 2750    (49.2) 
35-44 years 4832    (9.9) 3169    (32.6) 2818    (10.5) 1763    (31.5) 
45-54 years 9051    (18.5) 1323    (13.6) 4981    (18.6) 699     (12.5) 
55-64 years 12237   (25.0) 501     (5.2) 6495    (24.3) 252     (4.5) 
65-74 years 13004   (26.6) 170     (1.7) 7090    (26.5) 99      (1.8) 
75+ years 8564    (17.5) 39      (0.4) 4598    (17.2) 25      (0.4) 
Age (mean, SD) 61.2    (13.1) 37.6    (10.1) 60.8    (13.3) 37.1    (10.0) 
Townsend deprivation score 
(mean, SD) 
0.5      (3.5) 0.2      (3.5) .8      (3.8) .5      (3.7) 
 
 
ethnicity       
ethnicity recorded 31662   (64.8) 6844    (70.4) 17229   (64.4) 3941    (70.5) 
White or not recorded 40987   (83.8) 8975    (92.3) 22361   (83.6) 5107    (91.4) 
Indian 1676    (3.4) 135     (1.4) 907     (3.4) 79      (1.4) 
Pakistani 1002    (2.0) 98      (1.0) 389     (1.5) 38      (0.7) 
Bangladeshi 704     (1.4) 80      (0.8) 633     (2.4) 59      (1.1) 
Other Asian 672     (1.4) 54      (0.6) 437     (1.6) 40      (0.7) 
Caribbean 1399    (2.9) 91      (0.9) 665     (2.5) 53      (0.9) 
Black African 1209    (2.5) 132     (1.4) 700     (2.6) 112     (2.0) 
Chinese 200     (0.4) 15      (0.2) 116     (0.4) 13      (0.2) 
Other 1040    (2.1) 144     (1.5) 551     (2.1) 87      (1.6) 
smoking status     
smoking status recorded 47415   (97.0) 9559    (98.3) 25933   (96.9) 5492    (98.3) 
non smoker 27390   (56.0) 5469    (56.2) 15035   (56.2) 3140    (56.2) 
Ex-smoker 11364   (23.2) 1545    (15.9) 6018    (22.5) 880     (15.7) 
light smoker 4861    (9.9) 1401    (14.4) 2777    (10.4) 776     (13.9) 
moderate smoker 1940    (4.0) 647     (6.7) 1093    (4.1) 400     (7.2) 
heavy smoker 1860    (3.8) 497     (5.1) 1010    (3.8) 296     (5.3) 
medical history & values     
family history CHD under 60 years 4839    (9.9) 1100    (11.3) 2745    (10.3) 636     (11.4) 
rheumatoid arthritis 954     (2.0) 110     (1.1) 517     (1.9) 46      (0.8) 
chronic renal disease 810     (1.7) 103     (1.1) 548     (2.0) 72      (1.3) 
treated hypertension 13094   (26.8) 740     (7.6) 7008    (26.2) 367     (6.6) 
atrial fibrillation 1048    (2.1) 17      (0.2) 578     (2.2) 8       (0.1) 
BMI recorded 45256   (92.6) 9307    (95.7) 24827   (92.8) 5346    (95.7) 
SBP recorded 47939   (98.1) 9598    (98.7) 26253   (98.1) 5513    (98.7) 
cholesterol ratio recorded 38271   (78.3) 7897    (81.2) 24097   (90.1) 5057    (90.5) 
HBA1C recorded  45442   (92.9) 9184    (94.4) 24925   (93.1) 5238    (93.7) 
BMI mean (SD) 29.1    (5.2) 26.4    (4.7) 29.1    (5.2) 26.5    (4.8) 
cholesterol ratio mean (SD) 4.2     (1.4) 3.4     (1.2) 4.2     (1.4) 3.5     (1.2) 
systolic blood pressure mean (SD) 142.6   (20.4) 128.5   (17.6) 142.1   (20.7) 128.4   (17.9) 
HBA1C mmol/l mean (SD) 61.9    (20.7) 70.4    (19.9) 62.5    (20.9) 71      (20.3) 
 
 
5.2 Incidence rates for CVD events 
 
Table 4 shows the number of incident cases, total and median person years of follow-up & 
crude and age standardized CVD incidence rates for patients with type 1 and type 2 diabetes 
in the derivation and validation cohort. In patients with type 2 diabetes in the derivation 
cohort, there were 10,643 incident CVD events arising from 327,367 person years of 
observation giving a crude rate of 28.4 per 1000 person years. 
 
 
 
Table 4: incidence rates for CVD events in derivation and validation cohort 
  Derivation cohort Validation cohort 
    
Type 1 Incident CVD cases 795 465 
 Person years 72,842 40,626 
 crude  incidence rate per 1000 pyrs 10.9 (10.8 to 11.7 ) 11.5 (10.5 to 12.5 ) 
 Age standardised rate per 1000 pyrs 33.9 (28.0 to 39.9) 39.5 (32.0 to 47.1) 
 median follow up (years) 6.4 6.0 
    
Type 2 Incident CVD cases 10,643 5,771 
 Person years 327,367 173,775 
 crude  incidence rate per 1000 pyrs 32.5 (31.9 to 33.1 ) 33.2 (32.4 to 34.1 ) 
 Age standardised rate per 1000 pyrs 28.4 (27.9 to 29.0) 28.9 (28.1 to 29.6) 
 median follow up (years) 5.33 5.02 
 
5.3 Distribution of CVD risk 
In the validation cohort, 83% of patients with type 2 diabetes have a 10 year risk of CVD 
using QRISK2-2014 of 10% or more.  
5.4 Validation statistics: discrimination 
 
Table 5 shows performance statistics using QRISK2 (2014) in the validation cohort.  
We tested the scores patients with type 1 and patients with type 2 diabetes. The 
performance statistics were highest in patients with type 1 diabetes.  
 
Table 5 validation statistics for QRISK2-2014  
 Women 
mean (95% CI) 
Men 
mean (95% CI) 
type 1    
R
2
 40.8 (33.2 to 48.4) 48.1 (42.0 to 54.3) 
D statistic 1.698 (1.432 to 1.965) 1.972 (1.729 to 2.215) 
ROC value 0.822 (0.788 to 0.856) 0.841 (0.812 to 0.872) 
Type 2    
R
2
 23.2 (21.0 to 25.4) 20.2 (18.2 to 22.2) 
D statistic 1.124 (1.054 to 1.195) 1.031 (0.967 to 1.095) 
ROC value 0.703 (0.691 to 0.715) 0.696 (0.685 to 0.706) 
 
There was no significant improvement for a model which included HBA1C and duration of 
diabetes. We also tested QRISK2-2014 in an separate database called the Clinical Research 
Practice Data Link (CPRD). The results were similar to those shown in Table 5. 
 
 
 
5.5 Validation statistics: calibration 
 
The next two graphs show the observed and mean predicted risks of CVD across the tenths 
of predicted risk using QRISK2-2014. The results show that QRISK2-2014 is well calibrated in 
patient with type 1 diabetes and those with type 2 diabetes.   
 
Figure 1 Calibration of QRISK2-2014 in subset of patients with type 1 diabetes 
 
 
Figure 2 Calibration of QRISk2-2014  in subset of patients with type 2 diabetes 
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6 Conclusion  
 
We have reviewed the published evidence used as the basis for recommending UKPDS for 
cardiovascular risk assessment in patients with diabetes. There is no consistent evidence to 
support the superiority of UKPDS compared with Framingham and no information at all on 
the performance of the approach of summing the results of separate CHD and stroke 
models as recommended in this draft guidance. The validation of QRISK2-2014 in the subset 
of patients with either type 1 or type 2 diabetes is similar to that reported for UKPDS in 
comparable populations.   
 
Whilst the guideline states an advantage of UKPDS is the inclusion of HBA1C, this is only in 
the CHD model as it was not significant in the stroke model which is also recommended. The 
definition of duration of diabetes in UKPDS is unclear since the model was derived on a 
cohort of newly diagnosed diabetics. On the other hand, there are additional variables in 
QRISK2 which are not present in UKPDS which are known to affect CVD risk and improve 
performance of the tool at a population level while improving face validity for individuals. 
This includes deprivation, body mass index, a much more granular definition of ethnicity and 
smoking status, inclusion of chronic renal disease and rheumatoid arthritis.  
 
While differences in the accuracy of risk scores are relevant, perhaps the most import issue 
is to ensure that appropriate risk assessment occurs and that the process is as easy as 
possible for practitioners.  There are some clear practical advantages of using QRISK2 in 
patients with diabetes – QRISK2 is integrated into all four GP system suppliers and is 
accepted practice. QRISK2 is also updated annually and so can be recalibrated to changing 
incidence of CVD events over time. It can also take advantage of improvements of data 
quality and evolving requirements of NICE and other guidelines. From a clinician’s 
perspective, it makes it easier to have one tool such as QRISK2, which will work for all 
patients. This is particularly important when there are requirements, for example, to 
calculate CVD risk in patients who have both diabetes and rheumatoid arthritis. Should 
clinicians use a tool which includes both variables such as QRISK2 or use one such as UKPDS 
which ignores the increased risk associated with rheumatoid arthritis? Similarly, CVD risk 
assessment is required on patients up to the age of 84 years which is possible with QRISK2 
but not with UKPDS since UKPDS was derived from patients under the age of 66 years. 
 
A recommendation to stop using QRISK2 in people with diabetes and move to one derived 
from an unrepresentative hospital population, that is unfamiliar to GPs, cumbersome to use 
and with a limited range of variables important for individuals, is likely to disrupt the 
ambition for CVD risk assessment to be a routine part of clinical care.  
 
  
 
 
 
7 References  
 
1. National Clinical Guideline Centre. Lipid modification: cardiovascular risk assessment and 
the modification of blood lipids for the primary and secondary prevention of 
cardiovascular disease. London, 2014:286. 
2. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England 
and Wales: prospective derivation and validation of QRISK2. BMJ 
2008:bmj.39609.449676.25 doi: 10.1136/bmj.39609.449676.25[published Online 
First: Epub Date]|. 
3. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of 
coronary heart disease in Type II diabetes (UKPDS 56). Clinical Sciences 
2001;101(6):671-79  
4. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: Risk of Stroke in Type 2 Diabetes 
Estimated by the UK Prospective Diabetes Study Risk Engine. Stroke 
2002;33(7):1776-81 doi: 10.1161/01.str.0000020091.07144.c7[published Online 
First: Epub Date]|. 
5. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for 
predicting risk of ischaemic stroke in primary care and comparison with other risk 
scores: a prospective open cohort study. BMJ 2013;346 doi: 
10.1136/bmj.f2573[published Online First: Epub Date]|. 
6. Simmons RK, Sharp S, Boekholdt SM, et al. Evaluation of the Framingham Risk Score in the 
European Prospective Investigation of Cancer-Norfolk Cohort: Does Adding Glycated 
Hemoglobin Improve the Prediction of Coronary Heart Disease Events? Arch Intern 
Med 2008;168(11):1209-16 doi: 10.1001/archinte.168.11.1209[published Online 
First: Epub Date]|. 
7. Stephens JW, Ambler G, Vallance P, et al. Cardiovascular risk and diabetes. Are the 
methods of risk prediction satisfactory? European journal of cardiovascular 
prevention and rehabilitation : official journal of the European Society of Cardiology, 
Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and 
Exercise Physiology 2004;11(6):521-8  
8. Guzder RN, Gatling W, Mullee MA, et al. Prognostic value of the Framingham 
cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in 
newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med 
2005;22(5):554-62 doi: 10.1111/j.1464-5491.2005.01494.x[published Online First: 
Epub Date]|. 
9. Elkeles RS, Godsland IF, Feher MD, et al. Coronary calcium measurement improves 
prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: 
the PREDICT study. Eur Heart J 2008;29(18):2244-51 doi: 
10.1093/eurheartj/ehn279[published Online First: Epub Date]|. 
10. Simmons RK, Coleman RL, Price HC, et al. Performance of the UK Prospective Diabetes 
Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular 
Disease in the EPIC- Norfolk Cohort. Diabetes Care 2009;32(4):708-13 doi: 
10.2337/dc08-1918[published Online First: Epub Date]|. 
 
 
 
7.1 Acknowledgements 
 
We acknowledge the contribution of EMIS practices who contribute to QResearch® and to 
the University of Nottingham and EMIS for expertise in establishing, developing and 
supporting the database.  
 
7.2 Contributorship 
 
JHC initiated the study, undertook the literature review, data extraction, data manipulation 
and primary data analysis and write the first draft of the paper. CC contributed to the 
design, analysis, interpretation and drafting of the paper. PB contributed to the 
development of core ideas, the analysis plan, the interpretation of the results and the 
drafting of the paper.  
7.3 Funding 
 
None.  
7.4 Competing Interests  
 
JHC is professor of clinical epidemiology at the University of Nottingham and co-director of 
QResearch® – a not-for-profit organisation which is a joint partnership between the 
University of Nottingham and EMIS (leading commercial supplier of IT for 60% of general 
practices in the UK). JHC is also director of ClinRisk Ltd which produces open and closed 
source software to ensure the reliable and updatable implementation of clinical risk 
algorithms within clinical computer systems to help improve patient care. CC is associate 
professor of Medical Statistics at the University of Nottingham and a consultant statistician 
for ClinRisk Ltd. PB has received no financial support for undertaking this work. This work 
and any views expressed within it are solely those of the co-authors and not of any affiliated 
bodies or organisations. There are no other relationships or activities that could appear to 
have influenced the submitted work.  
 
